Laura García-Pupo, Lucie Crouzier, Alberto Bencomo-Martínez, Johann Meunier, Axelle Morilleau, Benjamin Delprat, . . . Chryslaine Rodríguez-Tanty. (2024). Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein. Elsevier.
Chicago Style (17th ed.) CitationLaura García-Pupo, et al. Amylovis-201 Is a New Dual-target Ligand, Acting as an Anti-amyloidogenic Compound and a Potent Agonist of the σ1 Chaperone Protein. Elsevier, 2024.
MLA (9th ed.) CitationLaura García-Pupo, et al. Amylovis-201 Is a New Dual-target Ligand, Acting as an Anti-amyloidogenic Compound and a Potent Agonist of the σ1 Chaperone Protein. Elsevier, 2024.
Warning: These citations may not always be 100% accurate.